Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer
Phase II study evaluates treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive blood cancer
The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) targets the CD123 antigen, which is overexpressed in BPDCN
PVEK monotherapy demonstrated strong responses, enabling ability to proceed with stem cell transplant for high-risk subgroup of patients with BPDCN
Seventy-five percent of patients...
Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus
Glioblastoma is a deadly brain cancer that suppresses the immune system and doesn’t respond well to available therapies
Researchers engineered...
First-in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
The novel cell therapy, called RB-1355, appears safe and well tolerated
RB-1355 offers unique advantages, such as being ready in about one week...
Americans prefer to screen for cervical cancer in-clinic vs. at home
More than 60% of American women prefer to get their cervical cancer screening in a clinic versus at home with a self-sampling kit, study finds
Black women are less likely to prefer at-home cervical cancer screening
In May, the FDA approved the first home-based self-sampling device for cervical cancer screening
HOUSTON, FEBRUARY 6, 2026 – American women now have the option of screening for cervical cancer at home, using newly approved...
Study shows strong evidence for effectiveness of metastasis-directed radiation therapy in prostate cancer
Metastasis-directed therapy (MDT) significantly improved progression-free survival and later endpoints
Data indicate statistically significant...
Blood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancer
Brain metastases are a common complication of inflammatory breast cancer
High levels of soluble E-cadherin in the blood are associated with...
Study reveals synergistic effect of CDK2 and CDK4/6 combination therapy
This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use...
Engineered nanobodies improved respiratory defenses in preclinical study
There are no current therapies designed to improve protection against multiple different respiratory viruses
Engineered nanobodies improved...
Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch Syndrome
Lynch Syndrome significantly increases the lifetime risk of developing multiple cancers, including colorectal and endometrial
NOUS-209...
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy
More than 90% of patients had a complete response to novel treatment combination
After two years, 97% of patients remained...
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
Linavonkibart, also known as SRK-181, is an experimental therapy from Scholar Rock that aims to prevent or overcome resistance to immune checkpoint...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Researchers studied the KDM6A gene, which is altered in about 26% of advanced bladder cancers
Tumors with KDM6A mutations did not respond well...
Higher bacteria levels inside tumors can promote immunotherapy resistance in head and neck cancer
Researchers found that the amount, and not the type, of bacteria inside tumors can predict response to treatment in lab...
Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting...
Immunotherapy before and after surgery improved outcomes in lung cancer patients with lymph node metastases
Perioperative nivolumab plus neoadjuvant chemotherapy improved outcomes for patients regardless of...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Phase II ETCTN trial found ipilimumab plus nivolumab did not improve outcomes over nivolumab alone in...
Researchers identify novel therapeutic target to improve recovery after nerve injury
Peripheral nerve injury reduces the ability of macrophages to clear dead or dying cells – a process known as efferocytosis – leading to chronic...
High levels of protein drive tumor immune suppression in head and neck cancer
BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment
Glutamine...
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Phase III COMMIT trial evaluated better first-line options for patients with dMMR/MSI-H metastatic colorectal cancer
The study...
Circadian rhythms may affect risk of bacterial infection
Researchers identified an inflammation biomarker in laboratory model that predicts which individuals are at an increased risk of bacterial infection...